Drug intelligence / Profile preview

Lactobacillus paracasei HA-196

Development stage: Unknown
Lead developer: KGK Science
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Lactobacillus paracasei HA-196 (recently reclassified as Lacticaseibacillus paracasei HA-196) is a specific probiotic bacterial strain developed by Lallemand Health Solutions. It is primarily utilized for its potential therapeutic benefits in managing gastrointestinal disorders, particularly Irritable Bowel Syndrome (IBS). The strain works by modulating the gut microbiota, enhancing intestinal barrier function, and potentially influencing the gut-brain axis to alleviate symptoms such as abdominal pain, bloating, and irregular bowel movements. It has been evaluated in clinical trials, such as NCT02213172, both as a monotherapy and in combination with other probiotic strains like Bifidobacterium longum R0175. HA-196 is commercially available as an ingredient in various dietary supplements and nutraceutical formulations aimed at supporting digestive health.

Other names: Lacticaseibacillus paracasei HA-196

Beyond the preview

Go deeper on Lactobacillus paracasei HA-196.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lactobacillus paracasei HA-196.

Explore the full profile